Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of macular diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion, significantly reducing visual impairment worldwide [1]. Here, VEGFA is linked to retinal vein occlusion.